Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phentermine/topiramate - VIVUS

Drug Profile

Phentermine/topiramate - VIVUS

Alternative Names: Phentermine and topiramate extended-release capsules - VIVUS; Phentermine/CR topiramate - VIVUS; Qnexa; Qsiva; Qsymia; Topiramate/phentermine; VI-0521

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VIVUS
  • Developer Alvogen; VIVUS
  • Class Amphetamines; Anorectics; Hexoses; Ketoses; Small molecules; Sulfonic acids
  • Mechanism of Action Adrenergic receptor agonists; AMPA receptor antagonists; Carbonic anhydrase inhibitors; Central nervous system stimulants; GABA A receptor agonists; Glutamate agonists; Kainic acid receptor antagonists; Neurotransmitter stimulants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Obesity
  • Phase II Sleep apnoea syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 07 Oct 2019 European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland accept MAA on a decentralised basis for phentermine/topiramate for Obesity
  • 07 Oct 2019 VIVUS anticipates the completion of the MAA assessment and Marketing Authorizations to begin in the second half of 2020
  • 20 Aug 2019 Efficacy and safety data from a phase II trial in Obesity released by VIVUS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top